Kennon Heard
Concepts (635)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acetaminophen | 39 | 2023 | 244 | 9.290 |
Why?
| Chemical and Drug Induced Liver Injury | 15 | 2023 | 136 | 5.270 |
Why?
| Analgesics, Non-Narcotic | 20 | 2022 | 116 | 4.860 |
Why?
| Drug Overdose | 30 | 2022 | 294 | 4.490 |
Why?
| Emergency Service, Hospital | 40 | 2023 | 1865 | 3.890 |
Why?
| Poisoning | 17 | 2017 | 109 | 3.370 |
Why?
| Poison Control Centers | 11 | 2023 | 84 | 2.960 |
Why?
| Alanine Transaminase | 14 | 2023 | 152 | 2.890 |
Why?
| Acetylcysteine | 11 | 2023 | 148 | 2.860 |
Why?
| Cannabis | 9 | 2020 | 382 | 2.720 |
Why?
| Cocaine | 10 | 2011 | 158 | 2.680 |
Why?
| Prescription Drugs | 9 | 2018 | 113 | 2.450 |
Why?
| Analgesics, Opioid | 8 | 2023 | 794 | 1.790 |
Why?
| Antidotes | 9 | 2020 | 126 | 1.690 |
Why?
| Legislation, Drug | 5 | 2017 | 78 | 1.640 |
Why?
| Cysteine | 4 | 2017 | 184 | 1.540 |
Why?
| Antipsychotic Agents | 7 | 2019 | 193 | 1.470 |
Why?
| Marijuana Use | 4 | 2021 | 157 | 1.420 |
Why?
| Male | 101 | 2022 | 57801 | 1.340 |
Why?
| Medication Errors | 5 | 2015 | 92 | 1.290 |
Why?
| Humans | 152 | 2023 | 118974 | 1.240 |
Why?
| Cocaine-Related Disorders | 5 | 2011 | 107 | 1.220 |
Why?
| Toxicology | 4 | 2021 | 35 | 1.200 |
Why?
| Pain | 9 | 2020 | 735 | 1.190 |
Why?
| Emergency Medicine | 6 | 2019 | 238 | 1.180 |
Why?
| Drug Packaging | 2 | 2017 | 44 | 1.180 |
Why?
| Female | 95 | 2022 | 61565 | 1.170 |
Why?
| Adult | 73 | 2022 | 31512 | 1.170 |
Why?
| Medication Reconciliation | 2 | 2016 | 25 | 1.080 |
Why?
| Dose-Response Relationship, Drug | 16 | 2017 | 1945 | 1.040 |
Why?
| Antidepressive Agents, Tricyclic | 5 | 2014 | 29 | 1.000 |
Why?
| Spider Bites | 5 | 2019 | 10 | 0.990 |
Why?
| Diphenhydramine | 4 | 2023 | 29 | 0.980 |
Why?
| Akathisia, Drug-Induced | 2 | 2020 | 6 | 0.960 |
Why?
| Antivenins | 5 | 2019 | 54 | 0.950 |
Why?
| Middle Aged | 54 | 2022 | 27617 | 0.940 |
Why?
| Thiazoles | 4 | 2009 | 121 | 0.940 |
Why?
| Young Adult | 30 | 2020 | 10793 | 0.930 |
Why?
| Prescription Drug Monitoring Programs | 1 | 2023 | 11 | 0.930 |
Why?
| Spider Venoms | 4 | 2019 | 12 | 0.920 |
Why?
| Heart Arrest | 8 | 2018 | 291 | 0.900 |
Why?
| Muscarinic Antagonists | 3 | 2023 | 25 | 0.890 |
Why?
| Benzodiazepines | 5 | 2011 | 122 | 0.880 |
Why?
| Referral and Consultation | 2 | 2020 | 648 | 0.880 |
Why?
| Decision Support Systems, Clinical | 2 | 2023 | 178 | 0.880 |
Why?
| Seizures | 6 | 2011 | 345 | 0.860 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 304 | 0.830 |
Why?
| Physostigmine | 2 | 2020 | 10 | 0.830 |
Why?
| Piperazines | 4 | 2009 | 316 | 0.820 |
Why?
| Lorazepam | 2 | 2020 | 24 | 0.820 |
Why?
| Emergency Treatment | 4 | 2015 | 110 | 0.820 |
Why?
| Delirium | 2 | 2020 | 70 | 0.810 |
Why?
| Black Widow Spider | 4 | 2019 | 9 | 0.810 |
Why?
| Medical History Taking | 3 | 2018 | 120 | 0.800 |
Why?
| Dopamine Uptake Inhibitors | 3 | 2011 | 53 | 0.800 |
Why?
| Suicide, Attempted | 5 | 2012 | 316 | 0.770 |
Why?
| Abdominal Pain | 2 | 2019 | 133 | 0.760 |
Why?
| Anti-Arrhythmia Agents | 4 | 2014 | 113 | 0.750 |
Why?
| Back Pain | 1 | 2020 | 44 | 0.740 |
Why?
| Retrospective Studies | 30 | 2022 | 12978 | 0.740 |
Why?
| Vasoconstrictor Agents | 4 | 2009 | 122 | 0.730 |
Why?
| Hospitals, Pediatric | 4 | 2018 | 505 | 0.730 |
Why?
| Buprenorphine | 2 | 2020 | 136 | 0.720 |
Why?
| Patient Handoff | 1 | 2020 | 27 | 0.720 |
Why?
| Free Radical Scavengers | 2 | 2011 | 88 | 0.710 |
Why?
| Ketorolac | 1 | 2019 | 18 | 0.690 |
Why?
| Haloperidol | 1 | 2019 | 36 | 0.690 |
Why?
| Social Work | 1 | 2020 | 69 | 0.680 |
Why?
| Pharmacoepidemiology | 1 | 2018 | 21 | 0.670 |
Why?
| Tertiary Care Centers | 3 | 2017 | 119 | 0.670 |
Why?
| Prospective Studies | 18 | 2023 | 6471 | 0.660 |
Why?
| Colorado | 15 | 2021 | 4196 | 0.660 |
Why?
| Gastric Lavage | 3 | 2009 | 9 | 0.650 |
Why?
| Vomiting | 6 | 2019 | 123 | 0.650 |
Why?
| Substance-Related Disorders | 5 | 2012 | 971 | 0.650 |
Why?
| Immunoglobulin Fab Fragments | 4 | 2019 | 69 | 0.640 |
Why?
| Child | 28 | 2023 | 19129 | 0.630 |
Why?
| Cannabinoids | 3 | 2017 | 115 | 0.620 |
Why?
| Drug Storage | 2 | 2017 | 59 | 0.620 |
Why?
| Hypotension | 2 | 2022 | 120 | 0.620 |
Why?
| Accidents, Home | 1 | 2017 | 32 | 0.600 |
Why?
| Pulmonary Embolism | 3 | 2021 | 183 | 0.600 |
Why?
| Medical Marijuana | 2 | 2019 | 102 | 0.600 |
Why?
| Plant Preparations | 2 | 2015 | 23 | 0.590 |
Why?
| Fibrin Fibrinogen Degradation Products | 2 | 2007 | 79 | 0.590 |
Why?
| Calcium Gluconate | 1 | 2016 | 4 | 0.590 |
Why?
| Quaternary Ammonium Compounds | 1 | 2016 | 46 | 0.570 |
Why?
| Hypocalcemia | 1 | 2016 | 31 | 0.570 |
Why?
| Mobile Applications | 1 | 2018 | 147 | 0.560 |
Why?
| Health Records, Personal | 1 | 2016 | 24 | 0.560 |
Why?
| Nonprescription Drugs | 4 | 2016 | 67 | 0.550 |
Why?
| Antidepressive Agents | 2 | 2012 | 189 | 0.550 |
Why?
| Practice Patterns, Physicians' | 3 | 2023 | 1200 | 0.550 |
Why?
| Blood Proteins | 1 | 2017 | 248 | 0.540 |
Why?
| Fat Emulsions, Intravenous | 2 | 2014 | 31 | 0.540 |
Why?
| Treatment Outcome | 18 | 2020 | 9342 | 0.530 |
Why?
| Liver | 6 | 2022 | 1816 | 0.530 |
Why?
| Prescription Drug Misuse | 1 | 2015 | 38 | 0.530 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 5 | 2023 | 245 | 0.520 |
Why?
| Child, Preschool | 13 | 2018 | 9491 | 0.520 |
Why?
| Emergency Medical Services | 4 | 2016 | 589 | 0.510 |
Why?
| Electrocardiography | 5 | 2013 | 556 | 0.510 |
Why?
| Infant | 12 | 2018 | 8293 | 0.510 |
Why?
| Adolescent | 27 | 2020 | 18480 | 0.480 |
Why?
| Asymptomatic Diseases | 2 | 2013 | 81 | 0.480 |
Why?
| Crime | 2 | 2011 | 60 | 0.480 |
Why?
| Electronic Health Records | 3 | 2023 | 829 | 0.480 |
Why?
| Observer Variation | 3 | 2010 | 309 | 0.480 |
Why?
| Arrhythmias, Cardiac | 3 | 2022 | 277 | 0.470 |
Why?
| Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 29 | 0.470 |
Why?
| Energy Drinks | 1 | 2013 | 4 | 0.470 |
Why?
| Double-Blind Method | 7 | 2020 | 1687 | 0.460 |
Why?
| Performance-Enhancing Substances | 1 | 2013 | 8 | 0.460 |
Why?
| Dronabinol | 4 | 2021 | 121 | 0.460 |
Why?
| Bradycardia | 1 | 2013 | 49 | 0.450 |
Why?
| Accidents | 1 | 2013 | 44 | 0.450 |
Why?
| Diet Surveys | 1 | 2013 | 85 | 0.450 |
Why?
| Poisons | 2 | 2023 | 21 | 0.450 |
Why?
| Plasmapheresis | 1 | 2013 | 23 | 0.450 |
Why?
| Aged | 27 | 2019 | 19657 | 0.450 |
Why?
| Hematemesis | 1 | 2012 | 3 | 0.450 |
Why?
| Amphotericin B | 1 | 2013 | 31 | 0.450 |
Why?
| Phytotherapy | 1 | 2013 | 69 | 0.450 |
Why?
| Stomach Diseases | 1 | 2012 | 17 | 0.450 |
Why?
| beta-Alanine | 1 | 2012 | 20 | 0.450 |
Why?
| Foreign Bodies | 2 | 2011 | 98 | 0.440 |
Why?
| Aspartate Aminotransferases | 3 | 2010 | 95 | 0.440 |
Why?
| Ethers | 1 | 2012 | 17 | 0.440 |
Why?
| Sulfonylurea Compounds | 2 | 2010 | 44 | 0.440 |
Why?
| Alcohol Drinking | 4 | 2012 | 652 | 0.440 |
Why?
| Antithrombins | 1 | 2012 | 51 | 0.430 |
Why?
| Citalopram | 1 | 2012 | 27 | 0.430 |
Why?
| Disease Models, Animal | 9 | 2011 | 3730 | 0.430 |
Why?
| Liver Function Tests | 7 | 2020 | 107 | 0.430 |
Why?
| Opioid-Related Disorders | 2 | 2020 | 417 | 0.420 |
Why?
| Drug Administration Schedule | 5 | 2014 | 736 | 0.420 |
Why?
| C-Peptide | 2 | 2010 | 137 | 0.420 |
Why?
| Antifungal Agents | 1 | 2013 | 134 | 0.420 |
Why?
| Propafenone | 1 | 2011 | 2 | 0.420 |
Why?
| Thiophenes | 1 | 2012 | 106 | 0.420 |
Why?
| Firesetting Behavior | 1 | 2011 | 1 | 0.410 |
Why?
| Genetic Predisposition to Disease | 1 | 2020 | 2275 | 0.410 |
Why?
| Burns | 2 | 2015 | 247 | 0.410 |
Why?
| Benzimidazoles | 1 | 2012 | 140 | 0.410 |
Why?
| Infusions, Intravenous | 6 | 2013 | 380 | 0.410 |
Why?
| Charcoal | 4 | 2006 | 23 | 0.410 |
Why?
| Clinical Enzyme Tests | 2 | 2013 | 11 | 0.410 |
Why?
| Aged, 80 and over | 15 | 2018 | 6561 | 0.400 |
Why?
| Temperance | 2 | 2010 | 15 | 0.400 |
Why?
| Administration, Intravenous | 4 | 2016 | 136 | 0.400 |
Why?
| Chemical and Drug Induced Liver Injury, Chronic | 1 | 2011 | 9 | 0.400 |
Why?
| Brain Edema | 1 | 2011 | 61 | 0.390 |
Why?
| Cholinergic Antagonists | 1 | 2011 | 28 | 0.390 |
Why?
| Amitriptyline | 2 | 2001 | 21 | 0.390 |
Why?
| Evidence-Based Medicine | 4 | 2023 | 693 | 0.380 |
Why?
| Self-Injurious Behavior | 1 | 2012 | 120 | 0.380 |
Why?
| Blood Chemical Analysis | 3 | 2021 | 95 | 0.380 |
Why?
| Liver Failure | 1 | 2011 | 85 | 0.380 |
Why?
| Immunologic Factors | 2 | 2019 | 225 | 0.380 |
Why?
| Tachycardia, Ventricular | 1 | 2012 | 151 | 0.380 |
Why?
| Anaphylaxis | 2 | 2012 | 146 | 0.370 |
Why?
| Hydrofluoric Acid | 2 | 2016 | 8 | 0.370 |
Why?
| Population Surveillance | 1 | 2013 | 413 | 0.370 |
Why?
| Pharmaceutical Vehicles | 1 | 2010 | 11 | 0.370 |
Why?
| Propylene Glycol | 1 | 2010 | 9 | 0.370 |
Why?
| Time Factors | 12 | 2020 | 6412 | 0.370 |
Why?
| Cross-Sectional Studies | 9 | 2020 | 4552 | 0.370 |
Why?
| Barium | 1 | 2009 | 27 | 0.370 |
Why?
| Acidosis, Lactic | 1 | 2010 | 29 | 0.360 |
Why?
| United States | 17 | 2023 | 12555 | 0.360 |
Why?
| Explosive Agents | 1 | 2009 | 9 | 0.360 |
Why?
| Surveys and Questionnaires | 4 | 2018 | 4708 | 0.360 |
Why?
| Liver Diseases, Alcoholic | 2 | 2007 | 87 | 0.360 |
Why?
| Imines | 2 | 2022 | 8 | 0.360 |
Why?
| Hypokalemia | 1 | 2009 | 31 | 0.360 |
Why?
| Warfarin | 1 | 2010 | 139 | 0.360 |
Why?
| Iatrogenic Disease | 1 | 2010 | 49 | 0.360 |
Why?
| Emetics | 2 | 2006 | 7 | 0.350 |
Why?
| Deception | 1 | 2009 | 15 | 0.350 |
Why?
| Risk Factors | 9 | 2017 | 9000 | 0.350 |
Why?
| Length of Stay | 3 | 2020 | 1032 | 0.350 |
Why?
| Random Allocation | 3 | 2007 | 344 | 0.350 |
Why?
| Benzoquinones | 2 | 2022 | 44 | 0.350 |
Why?
| Oximetry | 1 | 2009 | 84 | 0.340 |
Why?
| Risk Assessment | 8 | 2017 | 3057 | 0.340 |
Why?
| Hypothermia, Induced | 1 | 2009 | 68 | 0.330 |
Why?
| Odds Ratio | 7 | 2017 | 996 | 0.330 |
Why?
| Point-of-Care Systems | 1 | 2010 | 151 | 0.330 |
Why?
| Eyelashes | 1 | 2008 | 3 | 0.320 |
Why?
| Cyanoacrylates | 1 | 2008 | 4 | 0.320 |
Why?
| Intellectual Disability | 1 | 2009 | 136 | 0.320 |
Why?
| Hypoglycemia | 2 | 2010 | 400 | 0.320 |
Why?
| Adhesives | 1 | 2008 | 11 | 0.320 |
Why?
| Reference Values | 4 | 2017 | 774 | 0.320 |
Why?
| Detergents | 1 | 2008 | 44 | 0.320 |
Why?
| Cardiovascular System | 1 | 2009 | 127 | 0.310 |
Why?
| Animals | 20 | 2019 | 33381 | 0.310 |
Why?
| Publishing | 1 | 2009 | 131 | 0.310 |
Why?
| Polyethylene Glycols | 1 | 2012 | 578 | 0.310 |
Why?
| Brugada Syndrome | 1 | 2007 | 10 | 0.310 |
Why?
| Diazepam | 1 | 2007 | 23 | 0.310 |
Why?
| Clinical Laboratory Techniques | 1 | 2008 | 89 | 0.300 |
Why?
| Niacin | 1 | 2007 | 20 | 0.300 |
Why?
| Vitamin B Complex | 1 | 2007 | 37 | 0.300 |
Why?
| Pediatrics | 1 | 2015 | 985 | 0.300 |
Why?
| Mice, Inbred Strains | 4 | 2009 | 405 | 0.300 |
Why?
| Specimen Handling | 1 | 2008 | 165 | 0.290 |
Why?
| Thromboembolism | 1 | 2007 | 99 | 0.290 |
Why?
| Brain Infarction | 1 | 2006 | 23 | 0.290 |
Why?
| Analgesics | 4 | 2017 | 159 | 0.290 |
Why?
| Self Report | 4 | 2021 | 699 | 0.280 |
Why?
| Anticoagulants | 1 | 2010 | 559 | 0.280 |
Why?
| Hypoxia-Ischemia, Brain | 1 | 2006 | 26 | 0.280 |
Why?
| Nausea | 4 | 2014 | 107 | 0.280 |
Why?
| Randomized Controlled Trials as Topic | 5 | 2012 | 1244 | 0.280 |
Why?
| Decontamination | 1 | 2006 | 22 | 0.280 |
Why?
| Intention | 1 | 2007 | 142 | 0.280 |
Why?
| Amiodarone | 1 | 2005 | 24 | 0.270 |
Why?
| Venous Thrombosis | 1 | 2007 | 147 | 0.270 |
Why?
| Age Factors | 7 | 2017 | 2995 | 0.270 |
Why?
| Epilepsy | 2 | 2020 | 290 | 0.270 |
Why?
| Eating | 4 | 2017 | 369 | 0.270 |
Why?
| Vasospasm, Intracranial | 1 | 2005 | 18 | 0.270 |
Why?
| Databases, Factual | 1 | 2010 | 1231 | 0.270 |
Why?
| Acute Kidney Injury | 1 | 2012 | 709 | 0.270 |
Why?
| Sodium Nitrite | 1 | 2005 | 36 | 0.260 |
Why?
| Biomarkers | 7 | 2021 | 3588 | 0.260 |
Why?
| Hypoglycemic Agents | 2 | 2010 | 1032 | 0.260 |
Why?
| Drug Utilization | 5 | 2014 | 169 | 0.260 |
Why?
| Subarachnoid Hemorrhage | 1 | 2005 | 64 | 0.260 |
Why?
| Diagnostic Imaging | 1 | 2007 | 294 | 0.260 |
Why?
| Education, Medical | 2 | 2021 | 239 | 0.260 |
Why?
| Coma | 2 | 2006 | 32 | 0.250 |
Why?
| Reproducibility of Results | 5 | 2011 | 2874 | 0.250 |
Why?
| Insulin | 3 | 2019 | 2162 | 0.240 |
Why?
| Hospitals, Urban | 5 | 2021 | 129 | 0.240 |
Why?
| Case-Control Studies | 4 | 2022 | 3171 | 0.240 |
Why?
| Injections, Intraperitoneal | 4 | 2009 | 108 | 0.240 |
Why?
| Anti-Anxiety Agents | 2 | 2020 | 38 | 0.240 |
Why?
| Animal Experimentation | 1 | 2003 | 6 | 0.230 |
Why?
| Glasgow Coma Scale | 1 | 2004 | 150 | 0.230 |
Why?
| Fibrinolytic Agents | 2 | 2021 | 238 | 0.230 |
Why?
| Calcium Chloride | 1 | 2003 | 15 | 0.230 |
Why?
| Hospitals, Teaching | 3 | 2014 | 104 | 0.220 |
Why?
| Magnesium Sulfate | 1 | 2003 | 18 | 0.220 |
Why?
| Sensitivity and Specificity | 4 | 2010 | 1795 | 0.220 |
Why?
| Longevity | 3 | 2009 | 151 | 0.220 |
Why?
| Opiate Substitution Treatment | 2 | 2020 | 96 | 0.210 |
Why?
| Cardiopulmonary Resuscitation | 3 | 2018 | 225 | 0.210 |
Why?
| Umbilical Cord | 2 | 2021 | 84 | 0.210 |
Why?
| Placebos | 2 | 2014 | 202 | 0.210 |
Why?
| Desipramine | 1 | 2001 | 9 | 0.210 |
Why?
| Phenylurea Compounds | 1 | 2022 | 85 | 0.210 |
Why?
| Logistic Models | 3 | 2017 | 1901 | 0.210 |
Why?
| Narcotic Antagonists | 2 | 2020 | 136 | 0.210 |
Why?
| Hyperthermia, Induced | 1 | 2022 | 67 | 0.200 |
Why?
| Confidence Intervals | 4 | 2010 | 324 | 0.200 |
Why?
| Research Design | 3 | 2006 | 969 | 0.200 |
Why?
| Severity of Illness Index | 1 | 2009 | 2674 | 0.200 |
Why?
| Sinus Thrombosis, Intracranial | 1 | 2021 | 22 | 0.200 |
Why?
| Heart Atria | 1 | 2001 | 112 | 0.200 |
Why?
| Fractures, Bone | 2 | 2017 | 380 | 0.190 |
Why?
| Acute Disease | 2 | 2019 | 940 | 0.190 |
Why?
| Myocardial Contraction | 1 | 2001 | 339 | 0.180 |
Why?
| Immunoglobulin Fragments | 1 | 1999 | 15 | 0.180 |
Why?
| Lysergic Acid Diethylamide | 1 | 1999 | 2 | 0.180 |
Why?
| Droperidol | 1 | 1999 | 4 | 0.180 |
Why?
| Wisconsin | 1 | 2020 | 91 | 0.180 |
Why?
| Lithium Carbonate | 1 | 1999 | 6 | 0.180 |
Why?
| Serotonin Syndrome | 1 | 1999 | 6 | 0.180 |
Why?
| Scorpion Stings | 1 | 1999 | 1 | 0.180 |
Why?
| Serotonin Receptor Agonists | 1 | 1999 | 28 | 0.180 |
Why?
| Mass Screening | 1 | 2007 | 1052 | 0.180 |
Why?
| Nutritive Value | 1 | 2019 | 29 | 0.180 |
Why?
| Starch | 1 | 2019 | 24 | 0.180 |
Why?
| Ventricular Premature Complexes | 1 | 1999 | 23 | 0.180 |
Why?
| Geriatric Assessment | 2 | 2011 | 185 | 0.180 |
Why?
| Community Health Workers | 1 | 2020 | 49 | 0.180 |
Why?
| Cannabidiol | 1 | 2020 | 53 | 0.180 |
Why?
| Administration, Oral | 4 | 2019 | 756 | 0.170 |
Why?
| Thrombocytopenia | 1 | 2021 | 185 | 0.170 |
Why?
| Healthy Volunteers | 2 | 2019 | 201 | 0.170 |
Why?
| Metabolome | 1 | 2022 | 296 | 0.170 |
Why?
| Immune System | 1 | 2020 | 181 | 0.170 |
Why?
| Fallopian Tube Diseases | 1 | 1998 | 5 | 0.170 |
Why?
| Pregnancy, Tubal | 1 | 1998 | 4 | 0.170 |
Why?
| Abortifacient Agents, Nonsteroidal | 1 | 1998 | 19 | 0.170 |
Why?
| Alcoholism | 3 | 2011 | 717 | 0.170 |
Why?
| Munchausen Syndrome by Proxy | 1 | 1998 | 2 | 0.170 |
Why?
| Cohort Studies | 7 | 2023 | 5116 | 0.170 |
Why?
| Dietary Carbohydrates | 1 | 2019 | 153 | 0.170 |
Why?
| Sex Factors | 5 | 2022 | 1781 | 0.170 |
Why?
| Plant Extracts | 1 | 2020 | 165 | 0.160 |
Why?
| Snake Bites | 1 | 1999 | 53 | 0.160 |
Why?
| Anticonvulsants | 1 | 2020 | 184 | 0.160 |
Why?
| Chi-Square Distribution | 2 | 2017 | 525 | 0.160 |
Why?
| Faculty, Medical | 1 | 2021 | 252 | 0.160 |
Why?
| Sulfasalazine | 1 | 1998 | 21 | 0.160 |
Why?
| Drug Antagonism | 2 | 2009 | 8 | 0.160 |
Why?
| Dyspnea | 1 | 1999 | 201 | 0.160 |
Why?
| Fellowships and Scholarships | 1 | 2021 | 250 | 0.160 |
Why?
| Drug Interactions | 4 | 2014 | 352 | 0.150 |
Why?
| Out-of-Hospital Cardiac Arrest | 1 | 2018 | 79 | 0.150 |
Why?
| Drug Therapy, Combination | 3 | 2011 | 965 | 0.150 |
Why?
| Genome-Wide Association Study | 2 | 2023 | 1323 | 0.150 |
Why?
| Methotrexate | 1 | 1998 | 227 | 0.150 |
Why?
| Survival Rate | 3 | 2013 | 1720 | 0.150 |
Why?
| Gastrointestinal Agents | 1 | 1998 | 58 | 0.150 |
Why?
| Simulation Training | 1 | 2018 | 66 | 0.150 |
Why?
| Continuity of Patient Care | 1 | 2020 | 265 | 0.150 |
Why?
| Incidence | 4 | 2013 | 2424 | 0.150 |
Why?
| Hypnotics and Sedatives | 1 | 1998 | 136 | 0.150 |
Why?
| Dietary Fats | 1 | 2019 | 322 | 0.150 |
Why?
| Peptide Fragments | 1 | 2021 | 702 | 0.150 |
Why?
| Ammonium Compounds | 1 | 2016 | 2 | 0.150 |
Why?
| Pain Management | 2 | 2017 | 294 | 0.150 |
Why?
| Energy Intake | 1 | 2019 | 447 | 0.140 |
Why?
| Fluorides | 1 | 2016 | 47 | 0.140 |
Why?
| Clinical Trials as Topic | 2 | 2012 | 969 | 0.140 |
Why?
| Cytochrome P-450 CYP2E1 Inhibitors | 1 | 2016 | 5 | 0.140 |
Why?
| Prenatal Care | 1 | 2019 | 252 | 0.140 |
Why?
| Metabolic Clearance Rate | 2 | 2019 | 113 | 0.140 |
Why?
| Ventricular Fibrillation | 1 | 2016 | 51 | 0.140 |
Why?
| Mice | 7 | 2009 | 15520 | 0.140 |
Why?
| Half-Life | 2 | 2019 | 147 | 0.140 |
Why?
| Predictive Value of Tests | 3 | 2015 | 1868 | 0.140 |
Why?
| Survival Analysis | 3 | 2010 | 1267 | 0.140 |
Why?
| Pharmacovigilance | 1 | 2015 | 13 | 0.140 |
Why?
| Pilot Projects | 1 | 2020 | 1419 | 0.140 |
Why?
| Herniorrhaphy | 1 | 2016 | 52 | 0.130 |
Why?
| Milk | 1 | 2016 | 125 | 0.130 |
Why?
| Adverse Drug Reaction Reporting Systems | 1 | 2015 | 69 | 0.130 |
Why?
| Genetic Variation | 1 | 2020 | 926 | 0.130 |
Why?
| Calcium | 2 | 2016 | 1169 | 0.130 |
Why?
| Fatal Outcome | 2 | 2013 | 287 | 0.130 |
Why?
| Child Behavior | 1 | 2017 | 212 | 0.130 |
Why?
| Hemodialysis Units, Hospital | 1 | 1994 | 5 | 0.130 |
Why?
| Ondansetron | 1 | 2014 | 9 | 0.130 |
Why?
| Liver Failure, Acute | 1 | 2015 | 63 | 0.130 |
Why?
| Patient Simulation | 1 | 2014 | 30 | 0.130 |
Why?
| Models, Biological | 2 | 2015 | 1715 | 0.130 |
Why?
| Hydrocodone | 1 | 2014 | 15 | 0.130 |
Why?
| Cytochrome P-450 CYP2D6 | 1 | 2014 | 25 | 0.130 |
Why?
| Total Quality Management | 1 | 1994 | 61 | 0.120 |
Why?
| Personnel Staffing and Scheduling | 1 | 2015 | 81 | 0.120 |
Why?
| Internship and Residency | 2 | 2014 | 1001 | 0.120 |
Why?
| Transaminases | 1 | 2014 | 26 | 0.120 |
Why?
| Curriculum | 1 | 2021 | 910 | 0.120 |
Why?
| Prognosis | 3 | 2011 | 3443 | 0.120 |
Why?
| Physicians | 2 | 2020 | 794 | 0.120 |
Why?
| Oxycodone | 1 | 2014 | 45 | 0.120 |
Why?
| Remote Consultation | 1 | 2014 | 39 | 0.120 |
Why?
| Acute Pain | 1 | 2014 | 33 | 0.120 |
Why?
| Pregnancy Complications | 1 | 2019 | 448 | 0.120 |
Why?
| Guanfacine | 1 | 2013 | 2 | 0.120 |
Why?
| Clonidine | 1 | 2013 | 21 | 0.120 |
Why?
| Walking | 1 | 2017 | 415 | 0.120 |
Why?
| Vitamins | 1 | 2015 | 158 | 0.120 |
Why?
| International Normalized Ratio | 2 | 2011 | 45 | 0.120 |
Why?
| Indazoles | 1 | 2014 | 60 | 0.120 |
Why?
| Cesium | 1 | 2013 | 17 | 0.120 |
Why?
| Food | 1 | 2015 | 162 | 0.110 |
Why?
| Attitude of Health Personnel | 1 | 2020 | 992 | 0.110 |
Why?
| Deoxycholic Acid | 1 | 2013 | 20 | 0.110 |
Why?
| Lethargy | 1 | 2012 | 5 | 0.110 |
Why?
| Duloxetine Hydrochloride | 1 | 2012 | 9 | 0.110 |
Why?
| Pain Measurement | 4 | 2019 | 469 | 0.110 |
Why?
| Dabigatran | 1 | 2012 | 26 | 0.110 |
Why?
| Pyrazoles | 1 | 2016 | 363 | 0.110 |
Why?
| Chlorides | 1 | 2013 | 137 | 0.110 |
Why?
| Athletic Performance | 1 | 2013 | 46 | 0.110 |
Why?
| Sleep Stages | 1 | 2012 | 60 | 0.110 |
Why?
| Marijuana Abuse | 1 | 2015 | 209 | 0.110 |
Why?
| Tachycardia | 1 | 2012 | 48 | 0.110 |
Why?
| Mycoses | 1 | 2013 | 69 | 0.110 |
Why?
| Sulfhydryl Reagents | 1 | 2012 | 11 | 0.110 |
Why?
| Dizziness | 1 | 2012 | 70 | 0.110 |
Why?
| Patient Discharge | 2 | 2016 | 796 | 0.110 |
Why?
| Arsenicals | 1 | 2012 | 26 | 0.110 |
Why?
| Data Collection | 2 | 2013 | 658 | 0.100 |
Why?
| Sampling Studies | 1 | 2012 | 92 | 0.100 |
Why?
| Accidental Falls | 2 | 2011 | 154 | 0.100 |
Why?
| Drug Combinations | 1 | 2013 | 291 | 0.100 |
Why?
| Follow-Up Studies | 3 | 2010 | 4596 | 0.100 |
Why?
| Information Systems | 1 | 2011 | 66 | 0.100 |
Why?
| Sulfides | 1 | 2012 | 96 | 0.100 |
Why?
| Laparoscopy | 1 | 2016 | 417 | 0.100 |
Why?
| Marijuana Smoking | 1 | 2015 | 220 | 0.100 |
Why?
| Arabia | 1 | 2011 | 2 | 0.100 |
Why?
| Hepatic Encephalopathy | 1 | 2011 | 22 | 0.100 |
Why?
| Levamisole | 1 | 2011 | 20 | 0.100 |
Why?
| Structure-Activity Relationship | 1 | 2012 | 522 | 0.100 |
Why?
| Dietary Supplements | 1 | 2015 | 467 | 0.100 |
Why?
| Immunocompromised Host | 1 | 2013 | 200 | 0.100 |
Why?
| Drug Contamination | 1 | 2011 | 54 | 0.100 |
Why?
| Molecular Structure | 1 | 2012 | 459 | 0.100 |
Why?
| Pharmacogenetics | 1 | 2012 | 151 | 0.100 |
Why?
| Universities | 1 | 2013 | 347 | 0.100 |
Why?
| Sports | 1 | 2013 | 194 | 0.100 |
Why?
| Glipizide | 1 | 2010 | 6 | 0.090 |
Why?
| Laboratories, Hospital | 1 | 2010 | 13 | 0.090 |
Why?
| Hepatitis, Alcoholic | 1 | 2010 | 13 | 0.090 |
Why?
| Troponin | 1 | 2010 | 47 | 0.090 |
Why?
| Glyburide | 1 | 2010 | 36 | 0.090 |
Why?
| Crowding | 1 | 2010 | 38 | 0.090 |
Why?
| Drug Prescriptions | 2 | 2016 | 248 | 0.090 |
Why?
| Watchful Waiting | 1 | 2010 | 55 | 0.090 |
Why?
| Adjuvants, Immunologic | 1 | 2011 | 207 | 0.090 |
Why?
| Body Weight | 1 | 2014 | 934 | 0.090 |
Why?
| Intensive Care Units, Pediatric | 1 | 2011 | 157 | 0.090 |
Why?
| Quetiapine Fumarate | 1 | 2009 | 25 | 0.090 |
Why?
| Dibenzothiazepines | 1 | 2009 | 20 | 0.090 |
Why?
| Aripiprazole | 1 | 2009 | 18 | 0.090 |
Why?
| Risperidone | 1 | 2009 | 27 | 0.090 |
Why?
| Health Services Accessibility | 1 | 2015 | 781 | 0.090 |
Why?
| Potassium | 1 | 2009 | 132 | 0.090 |
Why?
| Workload | 1 | 2010 | 128 | 0.090 |
Why?
| Dogs | 1 | 2010 | 371 | 0.090 |
Why?
| Role | 1 | 2009 | 32 | 0.090 |
Why?
| Head Protective Devices | 1 | 2009 | 17 | 0.090 |
Why?
| Efficiency, Organizational | 1 | 2010 | 126 | 0.090 |
Why?
| Renal Dialysis | 1 | 2013 | 378 | 0.090 |
Why?
| Glutathione | 3 | 2022 | 324 | 0.090 |
Why?
| Quality Control | 1 | 2009 | 159 | 0.080 |
Why?
| Body Temperature | 1 | 2009 | 215 | 0.080 |
Why?
| Acidosis | 2 | 2006 | 86 | 0.080 |
Why?
| Bibliometrics | 1 | 2009 | 51 | 0.080 |
Why?
| Skiing | 1 | 2009 | 39 | 0.080 |
Why?
| Diarrhea | 1 | 2009 | 181 | 0.080 |
Why?
| Quality Indicators, Health Care | 1 | 2011 | 295 | 0.080 |
Why?
| Informed Consent | 2 | 2006 | 163 | 0.080 |
Why?
| Pharmacy Service, Hospital | 1 | 2009 | 86 | 0.080 |
Why?
| Students | 1 | 2013 | 509 | 0.080 |
Why?
| Acetone | 1 | 2008 | 10 | 0.080 |
Why?
| Hair Preparations | 1 | 2008 | 2 | 0.080 |
Why?
| Bacitracin | 1 | 2008 | 7 | 0.080 |
Why?
| Adhesiveness | 1 | 2008 | 19 | 0.080 |
Why?
| Nylons | 1 | 2008 | 18 | 0.080 |
Why?
| Propylene Glycols | 1 | 2008 | 27 | 0.080 |
Why?
| Cause of Death | 1 | 2010 | 380 | 0.080 |
Why?
| Withholding Treatment | 1 | 2008 | 67 | 0.080 |
Why?
| Quinolones | 1 | 2009 | 98 | 0.080 |
Why?
| Substance Abuse Detection | 2 | 2021 | 63 | 0.080 |
Why?
| Equipment Design | 1 | 2009 | 519 | 0.080 |
Why?
| Cellulose | 1 | 2008 | 64 | 0.080 |
Why?
| Glycerol | 1 | 2008 | 88 | 0.080 |
Why?
| Drug Synergism | 1 | 2008 | 339 | 0.080 |
Why?
| Nephelometry and Turbidimetry | 1 | 2007 | 16 | 0.080 |
Why?
| Polypharmacy | 1 | 2008 | 75 | 0.080 |
Why?
| Laboratories | 1 | 2008 | 97 | 0.080 |
Why?
| Military Personnel | 1 | 2014 | 529 | 0.070 |
Why?
| Hospitalization | 2 | 2011 | 1785 | 0.070 |
Why?
| Tissue Distribution | 2 | 2019 | 334 | 0.070 |
Why?
| Phosphates | 1 | 2008 | 167 | 0.070 |
Why?
| Formates | 1 | 2006 | 13 | 0.070 |
Why?
| Defibrillators | 1 | 2006 | 17 | 0.070 |
Why?
| Methanol | 1 | 2006 | 35 | 0.070 |
Why?
| Periodicals as Topic | 1 | 2009 | 191 | 0.070 |
Why?
| Research | 2 | 2011 | 411 | 0.070 |
Why?
| Combined Modality Therapy | 1 | 2009 | 1166 | 0.070 |
Why?
| Kidney Transplantation | 1 | 2013 | 585 | 0.070 |
Why?
| Blindness | 1 | 2006 | 35 | 0.070 |
Why?
| Statistics, Nonparametric | 1 | 2007 | 403 | 0.070 |
Why?
| Vasopressins | 1 | 2006 | 64 | 0.070 |
Why?
| Naproxen | 1 | 2006 | 12 | 0.070 |
Why?
| Aging | 2 | 2014 | 1670 | 0.070 |
Why?
| Probability | 2 | 2010 | 305 | 0.070 |
Why?
| Health Services for the Aged | 1 | 2006 | 71 | 0.070 |
Why?
| Ipecac | 1 | 2005 | 8 | 0.070 |
Why?
| Telemedicine | 1 | 2014 | 664 | 0.070 |
Why?
| Respiratory Insufficiency | 1 | 2009 | 290 | 0.070 |
Why?
| Spinal Diseases | 1 | 2006 | 47 | 0.070 |
Why?
| Population Dynamics | 1 | 2006 | 137 | 0.070 |
Why?
| Respiration, Artificial | 1 | 2009 | 545 | 0.070 |
Why?
| Geriatrics | 1 | 2006 | 68 | 0.070 |
Why?
| Epinephrine | 1 | 2006 | 167 | 0.070 |
Why?
| Ibuprofen | 1 | 2006 | 76 | 0.070 |
Why?
| Hospitals, University | 1 | 2006 | 172 | 0.070 |
Why?
| Haplorhini | 1 | 2005 | 62 | 0.070 |
Why?
| Premedication | 1 | 2005 | 40 | 0.070 |
Why?
| Practice Guidelines as Topic | 2 | 2014 | 1440 | 0.070 |
Why?
| Blood Glucose | 2 | 2019 | 1939 | 0.060 |
Why?
| Spine | 1 | 2006 | 144 | 0.060 |
Why?
| Water | 1 | 2008 | 425 | 0.060 |
Why?
| Motivation | 1 | 2009 | 506 | 0.060 |
Why?
| Risk | 1 | 2007 | 853 | 0.060 |
Why?
| Single-Blind Method | 1 | 2005 | 269 | 0.060 |
Why?
| Fluoride Poisoning | 1 | 2004 | 4 | 0.060 |
Why?
| Resuscitation | 1 | 2006 | 253 | 0.060 |
Why?
| Maltose | 1 | 2023 | 6 | 0.060 |
Why?
| Hydroxyzine | 1 | 2023 | 6 | 0.060 |
Why?
| Guidelines as Topic | 1 | 2005 | 262 | 0.060 |
Why?
| Health Policy | 1 | 2006 | 333 | 0.060 |
Why?
| Mycophenolic Acid | 1 | 2004 | 79 | 0.060 |
Why?
| Magnesium | 1 | 2004 | 150 | 0.060 |
Why?
| Pregnancy | 3 | 2021 | 5691 | 0.060 |
Why?
| Sheep | 1 | 2006 | 764 | 0.060 |
Why?
| Aspirin | 1 | 2006 | 334 | 0.060 |
Why?
| Urea | 1 | 2023 | 77 | 0.060 |
Why?
| Survival | 1 | 2003 | 39 | 0.060 |
Why?
| Patient Participation | 1 | 2006 | 369 | 0.050 |
Why?
| Internet | 1 | 2007 | 633 | 0.050 |
Why?
| Prevalence | 3 | 2015 | 2326 | 0.050 |
Why?
| Lactates | 1 | 2022 | 87 | 0.050 |
Why?
| Urban Population | 2 | 2019 | 409 | 0.050 |
Why?
| Canada | 1 | 2023 | 340 | 0.050 |
Why?
| Sex Distribution | 2 | 2015 | 351 | 0.050 |
Why?
| Culture Techniques | 1 | 2001 | 80 | 0.050 |
Why?
| Blood Physiological Phenomena | 1 | 2021 | 15 | 0.050 |
Why?
| Neural Conduction | 1 | 2001 | 81 | 0.050 |
Why?
| Academic Medical Centers | 2 | 2016 | 422 | 0.050 |
Why?
| Breast Neoplasms | 1 | 2013 | 1965 | 0.050 |
Why?
| Hirudins | 1 | 2021 | 46 | 0.050 |
Why?
| Controlled Clinical Trials as Topic | 1 | 2020 | 26 | 0.050 |
Why?
| Infusions, Parenteral | 1 | 2020 | 37 | 0.050 |
Why?
| Pirenzepine | 1 | 1999 | 8 | 0.040 |
Why?
| Scorpions | 1 | 1999 | 2 | 0.040 |
Why?
| Certification | 1 | 2020 | 99 | 0.040 |
Why?
| Immunosuppressive Agents | 1 | 2004 | 681 | 0.040 |
Why?
| Ambulatory Care | 1 | 2023 | 482 | 0.040 |
Why?
| South America | 1 | 1999 | 56 | 0.040 |
Why?
| Temperature | 1 | 2022 | 622 | 0.040 |
Why?
| Blood Cell Count | 2 | 2013 | 53 | 0.040 |
Why?
| Narcotics | 1 | 1999 | 50 | 0.040 |
Why?
| Biological Availability | 1 | 2019 | 126 | 0.040 |
Why?
| Postprandial Period | 1 | 2019 | 96 | 0.040 |
Why?
| Rupture, Spontaneous | 1 | 1998 | 18 | 0.040 |
Why?
| Manikins | 1 | 2018 | 26 | 0.040 |
Why?
| Videotape Recording | 1 | 2018 | 32 | 0.040 |
Why?
| Sorption Detoxification | 1 | 1998 | 3 | 0.040 |
Why?
| Central Nervous System Depressants | 1 | 1999 | 89 | 0.040 |
Why?
| North America | 1 | 1999 | 266 | 0.040 |
Why?
| Cholinesterase Inhibitors | 1 | 1998 | 26 | 0.040 |
Why?
| Dietary Proteins | 1 | 2019 | 130 | 0.040 |
Why?
| Analysis of Variance | 1 | 2001 | 1293 | 0.040 |
Why?
| Lipids | 1 | 2022 | 607 | 0.040 |
Why?
| Laparotomy | 1 | 1998 | 106 | 0.040 |
Why?
| Feedback | 1 | 2018 | 153 | 0.040 |
Why?
| Cross-Over Studies | 1 | 2019 | 456 | 0.040 |
Why?
| Recombinant Proteins | 1 | 2021 | 1308 | 0.040 |
Why?
| Maternal Health Services | 1 | 2019 | 83 | 0.040 |
Why?
| Central Nervous System | 1 | 1999 | 245 | 0.040 |
Why?
| Bipolar Disorder | 1 | 1999 | 209 | 0.040 |
Why?
| Triglycerides | 1 | 2019 | 519 | 0.040 |
Why?
| Socioeconomic Factors | 2 | 2015 | 1129 | 0.040 |
Why?
| Registries | 2 | 2010 | 1810 | 0.040 |
Why?
| Oxidation-Reduction | 1 | 2019 | 940 | 0.040 |
Why?
| Hallucinogens | 1 | 2017 | 74 | 0.030 |
Why?
| Dialysis | 1 | 2015 | 24 | 0.030 |
Why?
| Centrifugation | 1 | 2015 | 31 | 0.030 |
Why?
| Verapamil | 1 | 2014 | 32 | 0.030 |
Why?
| Tennessee | 1 | 1994 | 44 | 0.030 |
Why?
| Observation | 1 | 2014 | 50 | 0.030 |
Why?
| Hematocrit | 1 | 1994 | 91 | 0.030 |
Why?
| International Classification of Diseases | 1 | 2015 | 122 | 0.030 |
Why?
| Syndrome | 1 | 2015 | 344 | 0.030 |
Why?
| Program Evaluation | 1 | 2018 | 845 | 0.030 |
Why?
| Anesthetics, Local | 1 | 2014 | 85 | 0.030 |
Why?
| Protein Binding | 1 | 2020 | 1975 | 0.030 |
Why?
| Erythropoietin | 1 | 1994 | 82 | 0.030 |
Why?
| Warfare | 1 | 2014 | 77 | 0.030 |
Why?
| Injections, Intralesional | 1 | 2013 | 33 | 0.030 |
Why?
| Salicylates | 1 | 2013 | 32 | 0.030 |
Why?
| Hospitals, Veterans | 1 | 1994 | 246 | 0.030 |
Why?
| Urinalysis | 1 | 2013 | 68 | 0.030 |
Why?
| Iron | 1 | 1994 | 248 | 0.030 |
Why?
| Nursing Staff, Hospital | 1 | 1994 | 123 | 0.030 |
Why?
| Long QT Syndrome | 1 | 2013 | 57 | 0.030 |
Why?
| Hemoglobins | 1 | 1994 | 326 | 0.030 |
Why?
| Therapeutic Irrigation | 1 | 2012 | 67 | 0.030 |
Why?
| Receptors, Opioid, mu | 1 | 2012 | 52 | 0.030 |
Why?
| Cytochrome P-450 Enzyme System | 1 | 2012 | 111 | 0.030 |
Why?
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2011 | 7 | 0.030 |
Why?
| Agranulocytosis | 1 | 2011 | 31 | 0.030 |
Why?
| False Negative Reactions | 1 | 2011 | 57 | 0.020 |
Why?
| Computer Simulation | 1 | 2015 | 922 | 0.020 |
Why?
| Fluid Therapy | 1 | 2012 | 131 | 0.020 |
Why?
| Insulin Resistance | 1 | 2019 | 1180 | 0.020 |
Why?
| Toothache | 1 | 2010 | 5 | 0.020 |
Why?
| Disease Outbreaks | 1 | 2014 | 322 | 0.020 |
Why?
| Gas Chromatography-Mass Spectrometry | 1 | 2011 | 135 | 0.020 |
Why?
| Immunoassay | 1 | 2011 | 101 | 0.020 |
Why?
| Leukoencephalopathies | 1 | 2011 | 32 | 0.020 |
Why?
| Quality of Health Care | 1 | 2015 | 586 | 0.020 |
Why?
| Drug Administration Routes | 1 | 2010 | 42 | 0.020 |
Why?
| Models, Theoretical | 1 | 1994 | 556 | 0.020 |
Why?
| Insurance Coverage | 1 | 2012 | 208 | 0.020 |
Why?
| Injections, Intravenous | 1 | 2010 | 210 | 0.020 |
Why?
| Neurologic Examination | 1 | 2010 | 126 | 0.020 |
Why?
| Patient Education as Topic | 1 | 1994 | 699 | 0.020 |
Why?
| Age Distribution | 1 | 2010 | 362 | 0.020 |
Why?
| Kidney Failure, Chronic | 1 | 1994 | 516 | 0.020 |
Why?
| Intestines | 1 | 2012 | 332 | 0.020 |
Why?
| Polymorphism, Genetic | 1 | 2012 | 642 | 0.020 |
Why?
| Safety | 1 | 2010 | 304 | 0.020 |
Why?
| Precision Medicine | 1 | 2012 | 363 | 0.020 |
Why?
| Ethanol | 1 | 2012 | 575 | 0.020 |
Why?
| Triage | 1 | 2010 | 203 | 0.020 |
Why?
| Seasons | 1 | 2010 | 461 | 0.020 |
Why?
| Clinical Competence | 1 | 2014 | 951 | 0.020 |
Why?
| Regression Analysis | 1 | 2010 | 983 | 0.020 |
Why?
| Bilirubin | 1 | 2007 | 95 | 0.020 |
Why?
| Disease Management | 1 | 2011 | 571 | 0.020 |
Why?
| Pulse | 1 | 2006 | 27 | 0.020 |
Why?
| Metabolomics | 1 | 2012 | 550 | 0.020 |
Why?
| Blastomycosis | 1 | 2006 | 9 | 0.020 |
Why?
| Coronary Circulation | 1 | 2006 | 121 | 0.020 |
Why?
| Genotype | 1 | 2012 | 1882 | 0.020 |
Why?
| Contraindications | 1 | 2006 | 86 | 0.020 |
Why?
| Amyloidosis | 1 | 2006 | 40 | 0.020 |
Why?
| Biopsy, Fine-Needle | 1 | 2006 | 69 | 0.020 |
Why?
| European Union | 1 | 2005 | 9 | 0.020 |
Why?
| Electric Countershock | 1 | 2006 | 110 | 0.020 |
Why?
| Infant, Newborn | 2 | 2007 | 5255 | 0.020 |
Why?
| Fever | 1 | 2007 | 283 | 0.020 |
Why?
| Disaster Planning | 1 | 2006 | 76 | 0.020 |
Why?
| Emergencies | 1 | 2006 | 153 | 0.020 |
Why?
| United States Food and Drug Administration | 1 | 2005 | 175 | 0.020 |
Why?
| Administration, Inhalation | 1 | 2006 | 656 | 0.020 |
Why?
| Renal Insufficiency | 1 | 2006 | 150 | 0.020 |
Why?
| Pharmaceutical Preparations | 1 | 2006 | 167 | 0.020 |
Why?
| Swine | 1 | 2006 | 730 | 0.020 |
Why?
| Up-Regulation | 1 | 2007 | 872 | 0.020 |
Why?
| Mice, Inbred ICR | 1 | 2004 | 111 | 0.010 |
Why?
| Brain Injuries | 1 | 2009 | 484 | 0.010 |
Why?
| Phenotype | 1 | 2012 | 3003 | 0.010 |
Why?
| Lupus Nephritis | 1 | 2004 | 55 | 0.010 |
Why?
| In Vitro Techniques | 1 | 2004 | 1094 | 0.010 |
Why?
| Miosis | 1 | 1999 | 3 | 0.010 |
Why?
| Pupil | 1 | 1999 | 13 | 0.010 |
Why?
| Blood Pressure | 1 | 2006 | 1664 | 0.010 |
Why?
| Hemodynamics | 1 | 2004 | 1004 | 0.010 |
Why?
| Chronic Disease | 1 | 2004 | 1636 | 0.010 |
Why?
| Algorithms | 1 | 2004 | 1541 | 0.010 |
Why?
| Neoplasms | 1 | 2006 | 2179 | 0.010 |
Why?
|
|
Heard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|